Cumberland Pharmaceuticals Inc.
CPIX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $37,868 | $39,553 | $42,011 | $35,985 |
| % Growth | -4.3% | -5.9% | 16.7% | – |
| Cost of Goods Sold | $6,586 | $6,067 | $9,119 | $8,811 |
| Gross Profit | $31,282 | $33,486 | $32,892 | $27,174 |
| % Margin | 82.6% | 84.7% | 78.3% | 75.5% |
| R&D Expenses | $4,816 | $5,834 | $6,689 | $5,684 |
| G&A Expenses | $11,127 | $10,652 | $10,180 | $9,780 |
| SG&A Expenses | $28,150 | $29,104 | $26,841 | $24,795 |
| Sales & Mktg Exp. | $17,023 | $18,452 | $16,661 | $15,015 |
| Other Operating Expenses | $4,748 | $8,103 | $5,067 | $4,371 |
| Operating Expenses | $37,714 | $43,041 | $38,597 | $34,851 |
| Operating Income | -$6,432 | -$9,555 | -$5,705 | -$7,677 |
| % Margin | -17% | -24.2% | -13.6% | -21.3% |
| Other Income/Exp. Net | -$34 | $3,270 | $124 | $2,115 |
| Pre-Tax Income | -$6,466 | -$6,285 | -$5,581 | -$5,562 |
| Tax Expense | -$23 | $46 | $69 | $35 |
| Net Income | -$6,480 | -$6,279 | -$5,570 | -$3,508 |
| % Margin | -17.1% | -15.9% | -13.3% | -9.7% |
| EPS | -0.46 | -0.44 | -0.38 | -0.24 |
| % Growth | -4.5% | -15.8% | -58.3% | – |
| EPS Diluted | -0.46 | -0.44 | -0.38 | -0.24 |
| Weighted Avg Shares Out | 14,060 | 14,299 | 14,564 | 14,905 |
| Weighted Avg Shares Out Dil | 14,060 | 14,299 | 14,564 | 14,905 |
| Supplemental Information | – | – | – | – |
| Interest Income | $334 | $287 | $98 | $26 |
| Interest Expense | $606 | $668 | $586 | $98 |
| Depreciation & Amortization | $6,043 | $8,103 | $5,328 | $4,606 |
| EBITDA | $182 | $2,486 | $333 | -$858 |
| % Margin | 0.5% | 6.3% | 0.8% | -2.4% |